Genomtec S.A. (FRA:4VI)

Market Cap	19.47M -13.4%
Revenue (ttm)	3.52K +1,400.0%
Net Income	-2.58M
EPS	-0.17
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	125
Open	1.232
Previous Close	1.452
Day's Range	1.166 - 1.232
52-Week Range	0.712 - 2.210
Beta	n/a
RSI	59.52
Earnings Date	Apr 28, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 26
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4VI

Financial Performance

In 2024, Genomtec's revenue was 1,000, a change of 0.00% compared to the previous year's 1,000. Losses were -11.21 million, 24.4% more than in 2023.

Financial numbers in PLN